DelveInsight’s “Chronic Myelocytic Leukemia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Chronic Myelocytic Leukemia (CML), historical and forecasted epidemiology as well as the Chronic Myelocytic Leukemia (CML) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Chronic Myelocytic Leukemia Overview
Chronic myelogenous leukemia (CML), also known as chronic myeloid leukemia, is a cancer of the white blood cells. It is a form of leukemia characterized by the increased and unregulated growth of myeloid cells in the bone marrow and the accumulation of these cells in the blood. CML is a clonal bone marrow stem cell disorder in which a proliferation of mature granulocytes (neutrophils, eosinophils, and basophils) and their precursors is found. It is a type of myeloproliferative neoplasm associated with a characteristic chromosomal translocation called the Philadelphia chromosome.
Chronic Myelocytic Leukemia Epidemiology Facts and Insights:
About 15% of all new cases of leukemia are chronic myeloid leukemia. About 1 person in 526 will get CML in their lifetime in the United States. The average age at diagnosis of CML is around 64 years. Almost half of cases are diagnosed in people 65 and older.
Click here to learn more about Chronic Myelocytic Leukemia Market Landscape
The Report Covers the Chronic Myelocytic Leukemia Epidemiology Segmented by –
-
Chronic Myelocytic Leukemia prevalent cases
-
Chronic Myelocytic Leukemia incident cases
-
Chronic Myelocytic Leukemia treatment cases
-
Chronic Myelocytic Leukemia diagnosed cases
Chronic Myelocytic Leukemia Market Outlook
The Chronic Myelocytic Leukemia market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted Chronic Myelocytic Leukemia market trends by analyzing the impact of current Chronic Myelocytic Leukemia (CML) therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of the Chronic Myelocytic Leukemia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Chronic Myelocytic Leukemia market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Chronic Myelocytic Leukemia (CML) market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Companies in the Chronic Myelocytic Leukemia Market Include:
-
Amneal Pharmaceuticals
-
Astex Pharmaceuticals
-
Bristol Myers Squibb
-
Pfizer
-
Novartis
And many more
Chronic Myelocytic Leukemia Therapies Covered in the Report Include:
-
Imatinib Mesylate
-
Decitabine
-
Bosutinib
-
Omacetaxine Mepesuccinate
-
HQP1351
And many others
Learn more about the Key Companies and the Emerging Therapies in the Chronic Myelocytic Leukemia Market
Table of Contents
-
Key Insights
-
Report Introduction
-
Executive Summary of Chronic Myelocytic Leukemia
-
Disease Background and Overview
-
Epidemiology and patient population
-
Chronic Myelocytic Leukemia Emerging Therapies
-
Chronic Myelocytic Leukemia Market Outlook
-
Market Access and Reimbursement of Therapies
-
Market Drivers
-
Market Barriers
-
Appendix
-
Report Methodology
-
DelveInsight Capabilities
-
Disclaimer
Click here to read more about the report’s offerings @ Chronic Myelocytic Leukemia Market Outlook
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services